90 related articles for article (PubMed ID: 27830380)
1. Recovery of pan-genotypic and genotype-specific amino acid alterations in chronic hepatitis C after viral clearance: transition at the crossroad of metabolism and immunity.
Chang ML; Cheng ML; Chang SW; Tang HY; Chiu CT; Yeh CT; Shiao MS
Amino Acids; 2017 Feb; 49(2):291-302. PubMed ID: 27830380
[TBL] [Abstract][Full Text] [Related]
2. Recovery of lipid metabolic alterations in hepatitis C patients after viral clearance: Incomplete restoration with accelerated ω-oxidation.
Chang SW; Cheng ML; Shiao MS; Yeh CT; Wang CH; Fan CM; Chiu CT; Chang ML
J Clin Lipidol; 2018; 12(3):756-766. PubMed ID: 29574072
[TBL] [Abstract][Full Text] [Related]
3. Association between Leptin and Complement in Hepatitis C Patients with Viral Clearance: Homeostasis of Metabolism and Immunity.
Chang ML; Kuo CJ; Huang HC; Chu YY; Chiu CT
PLoS One; 2016; 11(11):e0166712. PubMed ID: 27870883
[TBL] [Abstract][Full Text] [Related]
4. Dynamics of serum metabolites in patients with chronic hepatitis C receiving pegylated interferon plus ribavirin: a metabolomics analysis.
Saito T; Sugimoto M; Igarashi K; Saito K; Shao L; Katsumi T; Tomita K; Sato C; Okumoto K; Nishise Y; Watanabe H; Tomita M; Ueno Y; Soga T
Metabolism; 2013 Nov; 62(11):1577-86. PubMed ID: 23953890
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis C virus selectively perturbs the distal cholesterol synthesis pathway in a genotype-specific manner.
Clark PJ; Thompson AJ; Vock DM; Kratz LE; Tolun AA; Muir AJ; McHutchison JG; Subramanian M; Millington DM; Kelley RI; Patel K
Hepatology; 2012 Jul; 56(1):49-56. PubMed ID: 22318926
[TBL] [Abstract][Full Text] [Related]
6. Impact of amino acid substitutions in the hepatitis C virus genotype 1b core region on liver steatosis and hepatic oxidative stress in patients with chronic hepatitis C.
Tachi Y; Katano Y; Honda T; Hayashi K; Ishigami M; Itoh A; Hirooka Y; Nakano I; Samejima Y; Goto H
Liver Int; 2010 Apr; 30(4):554-9. PubMed ID: 19951380
[TBL] [Abstract][Full Text] [Related]
7. A simple rule to personalize standard dual therapy across all genotypes in naive chronic hepatitis C patients: the TT4 randomized trial.
Francioso S; Almerighi C; Forte P; Bandiera F; Nosotti L; Lionetti R; Taliani G; Piras MR; Ponti ML; Parruti G; Di Candilo F; Gentile S; Piccolo P; Salso A; Riccobelli F; Renzi S; Longo MA; Montalbano M; Zaru S; Biliotti E; Di Masi F; Santopaolo F; Angelico M
Dig Liver Dis; 2014 Feb; 46(2):164-9. PubMed ID: 24239044
[TBL] [Abstract][Full Text] [Related]
8. Analysis of genotype 2 and 3 hepatitis C virus variants in patients treated with telaprevir demonstrates a consistent resistance profile across genotypes.
De Meyer S; Ghys A; Foster GR; Beumont M; Van Baelen B; Lin TI; Dierynck I; Ceulemans H; Picchio G
J Viral Hepat; 2013 Jun; 20(6):395-403. PubMed ID: 23647956
[TBL] [Abstract][Full Text] [Related]
9. Advanced hepatic fibrosis and steatosis are associated with persistent alanine aminotransferase elevation in chronic hepatitis C patients negative for hepatitis C virus RNA during pegylated interferon plus ribavirin therapy.
Liang CC; Liu CH; Chung CS; Lin CK; Su TH; Yang HC; Liu CJ; Chen PJ; Chen DS; Kao JH
J Infect Dis; 2015 May; 211(9):1429-36. PubMed ID: 25387585
[TBL] [Abstract][Full Text] [Related]
10. The Evolving Interplay among Abundant Adipokines in Patients with Hepatitis C during Viral Clearance.
Chang ML; Hsu CM; Lin CH; Lin CY; Kuo CJ; Huang SW; Chen CW; Cheng HT; Yeh CT; Chiu CT
Nutrients; 2017 Jun; 9(6):. PubMed ID: 28574439
[TBL] [Abstract][Full Text] [Related]
11. Analysis of variables and interactions among variables associated with a sustained virological response to pegylated interferon alfa-2a plus ribavirin in hepatitis C virus genotype 3-infected patients.
Aziz H; Raza A; Waheed Y; Gill U; Gill ML
Int J Infect Dis; 2012 Aug; 16(8):e597-602. PubMed ID: 22658873
[TBL] [Abstract][Full Text] [Related]
12. Rapid virological response assessment by Abbott RealTime hepatitis C virus assay for predicting sustained virological responses in patients with hepatitis C virus genotype 1 treated with pegylated-interferon and ribavirin.
Su PY; Yen HH; Hsu YC; Wu SS; Kor CT; Su WW
Kaohsiung J Med Sci; 2016 Jul; 32(7):381-6. PubMed ID: 27450028
[TBL] [Abstract][Full Text] [Related]
13. Association between HCV amino acid substitutions and outcome of peginterferon and ribavirin combination therapy in HCV genotype 1b and high viral load.
Toyoda H; Kumada T; Tada T; Arakawa T; Hayashi K; Honda T; Katano Y; Goto H
J Gastroenterol Hepatol; 2010 Jun; 25(6):1072-8. PubMed ID: 20594221
[TBL] [Abstract][Full Text] [Related]
14. Association of interferon-γ-induced protein-10 serum levels with virological responses to PEG-interferon-based therapy in hepatitis C virus genotype 1 or 2 chronically infected Chinese patients.
Wang J; Jiang D; Rao H; Yang R; Wang Y; Wei L
Scand J Gastroenterol; 2014 Nov; 49(11):1349-58. PubMed ID: 25263691
[TBL] [Abstract][Full Text] [Related]
15. Implications of rapid virological response in hepatitis C therapy in the US veteran population.
Hwang EW; Thomas IC; Cheung R; Backus LI
Aliment Pharmacol Ther; 2012 Jan; 35(1):105-15. PubMed ID: 22060887
[TBL] [Abstract][Full Text] [Related]
16. OPERA: responses to peginterferon and ribavirin therapy in a subgroup of interferon-naïve patients with HIV/HCV genotype 2/3 co-infection in Italy.
Bruno R; Cariti G; Nasta P; Capetti A; Ravasio V; Galli M; Raise E; Palmieri G; Iannacone C; Puoti M
Liver Int; 2015 Jan; 35(1):120-9. PubMed ID: 25041136
[TBL] [Abstract][Full Text] [Related]
17. Insulin resistance predicts rapid virologic response to peginterferon/ribavirin combination therapy in hepatitis C genotype 4 patients.
Khattab M; Eslam M; Sharwae MA; Shatat M; Ali A; Hamdy L
Am J Gastroenterol; 2010 Sep; 105(9):1970-7. PubMed ID: 20234345
[TBL] [Abstract][Full Text] [Related]
18. Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis.
Andriulli A; Mangia A; Iacobellis A; Ippolito A; Leandro G; Zeuzem S
Aliment Pharmacol Ther; 2008 Aug; 28(4):397-404. PubMed ID: 18549461
[TBL] [Abstract][Full Text] [Related]
19. Early identification of achieving a sustained virological response in chronic hepatitis C patients without a rapid virological response.
Huang CF; Yang JF; Huang JF; Dai CY; Chiu CF; Hou NJ; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Chuang WL; Yu ML
J Gastroenterol Hepatol; 2010 Apr; 25(4):758-65. PubMed ID: 20492331
[TBL] [Abstract][Full Text] [Related]
20. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C.
Furusyo N; Ogawa E; Nakamuta M; Kajiwara E; Nomura H; Dohmen K; Takahashi K; Satoh T; Azuma K; Kawano A; Tanabe Y; Kotoh K; Shimoda S; Hayashi J;
J Hepatol; 2013 Aug; 59(2):205-12. PubMed ID: 23542346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
